Seattle Genetics to Present at the J.P. Morgan Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 2:30 p.m. Pacific Time. Both the presentation and question and answer session that follows at 3:00 p.m. will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section.

About Seattle Genetics

Seattle Genetics is an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer. The company’s industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. ADCETRIS® (brentuximab vedotin), the company’s lead product, in collaboration with Takeda Pharmaceutical Company Limited, is the first in a new class of ADCs commercially available globally in 65 countries for relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics is also advancing vadastuximab talirine (SGN-CD33A; 33A), an ADC in a phase 3 trial for acute myeloid leukemia. Headquartered in Bothell, Washington, Seattle Genetics has a robust pipeline of innovative therapies for blood-related cancers and solid tumors designed to address significant unmet medical needs and improve treatment outcomes for patients. The company has collaborations for its proprietary ADC technology with a number of companies including AbbVie, Astellas, Bayer, Celldex, Genentech, GlaxoSmithKline and Pfizer. More information can be found at www.seattlegenetics.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161220005130/en/

Seattle Genetics, Inc.
Investors
Peggy Pinkston, 425-527-4160
[email protected]
or
Media
Brandi Robinson, 425-527-2910
[email protected]

Source: Seattle Genetics, Inc.

You May Also Be Interested In

• Belkruvozan Review 2026: Platform Features, Overview and Key Information
• SENIX Announces Prime Day Deal on 21-Inch Self-Propelled Gas Lawn Mower as Homeowners Tackle Peak Summer Yard Care
• Fast Millennial Mode Announces Its Inside Out Beauty Philosophy with the Launch of Sacred Eye Beauty